• Explore /
  • Poster
  • / Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

Abstract Poster

Authors

Saby George

Saby George

Roswell Park Comprehensive Cancer Center, Buffalo, NY

Saby George , James Larkin , Kateryna Chepynoga , Daniel Sharpe , Tuli De , Matthew Dyer , Flavia Ejzykowicz , Jessica May , Murat Kurt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Other

Clinical Trial Registration Number

NCT01668784

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 729)

DOI

10.1200/JCO.2023.41.6_suppl.729

Abstract #

729

Poster Bd #

L4

Abstract Disclosures

Similar Posters

First Author: Ruchit Shah

First Author: Robert J. Motzer

First Author: Robert J. Motzer

First Author: Bernard J. Escudier